Annual FCF
-$83.42 M
+$14.75 M+15.03%
December 31, 2024
Summary
- As of March 8, 2025, RAPT annual free cash flow is -$83.42 million, with the most recent change of +$14.75 million (+15.03%) on December 31, 2024.
- During the last 3 years, RAPT annual FCF has fallen by -$21.64 million (-35.02%).
- RAPT annual FCF is now -195.32% below its all-time high of -$28.25 million, reached on December 31, 2017.
Performance
RAPT Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$10.44 M
+$7.20 M+40.82%
December 31, 2024
Summary
- As of March 8, 2025, RAPT quarterly free cash flow is -$10.44 million, with the most recent change of +$7.20 million (+40.82%) on December 31, 2024.
- Over the past year, RAPT quarterly FCF has increased by +$16.75 million (+61.61%).
- RAPT quarterly FCF is now -82.71% below its all-time high of -$5.71 million, reached on December 31, 2019.
Performance
RAPT Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$83.42 M
+$17.38 M+17.24%
December 31, 2024
Summary
- As of March 8, 2025, RAPT TTM free cash flow is -$83.42 million, with the most recent change of +$17.38 million (+17.24%) on December 31, 2024.
- Over the past year, RAPT TTM FCF has increased by +$22.58 million (+21.30%).
- RAPT TTM FCF is now -935.75% below its all-time high of -$8.05 million, reached on March 31, 2018.
Performance
RAPT TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
RAPT Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +15.0% | +61.6% | +21.3% |
| 3 y3 years | -35.0% | +50.5% | -35.0% |
| 5 y5 years | -129.4% | -82.7% | -129.4% |
RAPT Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -35.0% | +15.0% | at high | +64.1% | -35.0% | +21.3% |
| 5 y | 5-year | -129.4% | +15.0% | -82.7% | +64.1% | -168.6% | +21.3% |
| alltime | all time | -195.3% | +15.0% | -82.7% | +64.1% | -935.8% | +21.3% |
RAPT Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$83.42 M(-15.0%) | -$10.44 M(-40.8%) | -$83.42 M(-17.2%) |
| Sep 2024 | - | -$17.64 M(-37.3%) | -$100.80 M(-4.1%) |
| Jun 2024 | - | -$28.15 M(+3.5%) | -$105.11 M(-0.8%) |
| Mar 2024 | - | -$27.19 M(-2.3%) | -$106.00 M(+8.0%) |
| Dec 2023 | -$98.17 M(+37.1%) | -$27.82 M(+26.7%) | -$98.17 M(+5.3%) |
| Sep 2023 | - | -$21.95 M(-24.4%) | -$93.25 M(+5.3%) |
| Jun 2023 | - | -$29.04 M(+50.0%) | -$88.53 M(+17.6%) |
| Mar 2023 | - | -$19.36 M(-15.4%) | -$75.25 M(+5.1%) |
| Dec 2022 | -$71.62 M(+15.9%) | -$22.90 M(+32.9%) | -$71.62 M(+2.6%) |
| Sep 2022 | - | -$17.23 M(+9.3%) | -$69.79 M(+7.1%) |
| Jun 2022 | - | -$15.76 M(+0.2%) | -$65.15 M(+2.8%) |
| Mar 2022 | - | -$15.73 M(-25.4%) | -$63.37 M(+2.6%) |
| Dec 2021 | -$61.78 M | -$21.07 M(+67.4%) | -$61.78 M(+9.8%) |
| Sep 2021 | - | -$12.59 M(-9.9%) | -$56.25 M(+4.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | -$13.98 M(-1.1%) | -$53.74 M(+16.4%) |
| Mar 2021 | - | -$14.14 M(-9.0%) | -$46.18 M(+12.9%) |
| Dec 2020 | -$40.89 M(+12.4%) | -$15.54 M(+54.2%) | -$40.89 M(+31.6%) |
| Sep 2020 | - | -$10.08 M(+56.8%) | -$31.06 M(-6.4%) |
| Jun 2020 | - | -$6.43 M(-27.3%) | -$33.20 M(-8.2%) |
| Mar 2020 | - | -$8.84 M(+54.8%) | -$36.15 M(-0.6%) |
| Dec 2019 | -$36.36 M(-0.2%) | -$5.71 M(-53.2%) | -$36.36 M(-12.4%) |
| Sep 2019 | - | -$12.21 M(+30.2%) | -$41.51 M(+6.6%) |
| Jun 2019 | - | -$9.38 M(+3.6%) | -$38.96 M(+4.0%) |
| Mar 2019 | - | -$9.05 M(-16.7%) | -$37.45 M(+2.7%) |
| Dec 2018 | -$36.45 M(+29.1%) | -$10.87 M(+12.5%) | -$36.45 M(+42.5%) |
| Sep 2018 | - | -$9.66 M(+22.7%) | -$25.59 M(+60.6%) |
| Jun 2018 | - | -$7.88 M(-2.2%) | -$15.93 M(+97.8%) |
| Mar 2018 | - | -$8.05 M | -$8.05 M |
| Dec 2017 | -$28.25 M | - | - |
FAQ
- What is RAPT Therapeutics annual free cash flow?
- What is the all time high annual FCF for RAPT Therapeutics?
- What is RAPT Therapeutics annual FCF year-on-year change?
- What is RAPT Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for RAPT Therapeutics?
- What is RAPT Therapeutics quarterly FCF year-on-year change?
- What is RAPT Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for RAPT Therapeutics?
- What is RAPT Therapeutics TTM FCF year-on-year change?
What is RAPT Therapeutics annual free cash flow?
The current annual FCF of RAPT is -$83.42 M
What is the all time high annual FCF for RAPT Therapeutics?
RAPT Therapeutics all-time high annual free cash flow is -$28.25 M
What is RAPT Therapeutics annual FCF year-on-year change?
Over the past year, RAPT annual free cash flow has changed by +$14.75 M (+15.03%)
What is RAPT Therapeutics quarterly free cash flow?
The current quarterly FCF of RAPT is -$10.44 M
What is the all time high quarterly FCF for RAPT Therapeutics?
RAPT Therapeutics all-time high quarterly free cash flow is -$5.71 M
What is RAPT Therapeutics quarterly FCF year-on-year change?
Over the past year, RAPT quarterly free cash flow has changed by +$16.75 M (+61.61%)
What is RAPT Therapeutics TTM free cash flow?
The current TTM FCF of RAPT is -$83.42 M
What is the all time high TTM FCF for RAPT Therapeutics?
RAPT Therapeutics all-time high TTM free cash flow is -$8.05 M
What is RAPT Therapeutics TTM FCF year-on-year change?
Over the past year, RAPT TTM free cash flow has changed by +$22.58 M (+21.30%)